Clinical Cognitive Neuroscience Center

Publication

Domestic

한국형 정신분열병 약물치료 알고리듬의 임상적용 가능성 (III): 정신분열병 약물치료에 대한 한국형 알고리듬의 적용에 치료환경이 미치는 영향
Journal
대한정신약물학회
Vol
17(2)
Page
149-161
Author
김승현, 이문수, 권준수, 박원명, 기백석, 안용민, 윤진상, 이중서, 조성남, 김용식
Year
2006

Objective:

In 2002, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP 2002) was published to make clinical guidelines to understand and treat bipolar disorder, but due to recent reports of various studies and application of new drugs, the revision of treatment algorithm was inevitable. Therefore, we revised the KMAP-BP 2002 focused on the treatment strategies of bipolar depression.

Method:

The methods of this survey were similar to those of the KMAP-BP 2002. The review committee consisted of 70 experienced psychi-atrists. Among the total 37 questions, 15 questions for bipolar depression were evaluated. We classified the expert opinions to 3 categories according to its confidence interval; first, second, and third line.

Results:

Compared to the previous algorithm, combination of mood stabilizers (MS) or atypical antipsychotics (AAP) and antidepressants is generally more recommended than antidepressant monotherapy for bipolar depression. Lithium and divalproex are the first-line treatment choices as well as MS. The preference for lamotrigine is increased, while that for carbamazepine is decreased. Olanzapine and quetiapine are preferred as the first-line AAP. Most antidepressants are not recommended as the first-line drug. The strategy for breakthrough of depression is changed into adding an antidepressant and/or AAP after combination of 2 MS.

Conclusion:

These results suggest that treatment of bipolar depression should be different from that of unipolar depression. The advanced new algorithm is considered to be useful and practical in the treatment of bipolar depression.